Dr. Chrisanna Dobrowolski, MD

Dr. Dobrowolski practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Dobrowolski's NPI, 1639619729, was assigned on March 8, 2017. Dr. Dobrowolski graduated from Dalhousie University, Faculty of Medicine in 2015. Dr. Dobrowolski holds New York license 304775.

Dr. Dobrowolski's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Dobrowolski also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Dobrowolski's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. Dr. Dobrowolski is also affiliated with Mount Sinai West. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Dr. Dobrowolski to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dobrowolski practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Dobrowolski's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Dobrowolski is licensed in New York.

CMS data shows 274 Medicare services from Dr. Dobrowolski across 4 procedure codes in 2024, for 98 Medicare patients. Medicare paid $12,322 for them.

CMS counts 98 Medicare patients who saw Dr. Dobrowolski in 2024. The largest group is 65 to 74, with 34 patients. 72% of them have high blood pressure, and 71% have high cholesterol. 42% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dobrowolski's median patient age at 56, with 77% women.

In 2024, Dr. Dobrowolski wrote 2,240 Medicare Part D claims for 249 patients. 88% of them were for generic drugs. CMS names the drug for 2,051 of them, across 30 drugs with 11 or more claims each, at $806,630 in total drug cost. In 2023, CMS named 1,820 claims across 28 drugs.

Dr. Dobrowolski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dobrowolski as offering telehealth.

Dmand AI links 10 papers to Dr. Dobrowolski, published from 2018 to 2025. 2024 was the busiest year, with 2. The most frequent topics are Lupus Erythematosus, Systemic, Lupus Nephritis and Anticoagulants. Dr. Dobrowolski has published most often in Adv Clin Chem. Dr. Dobrowolski's most frequent co-authors are Cynthia B. Aranow, MD, Yashaar Chaichian, MD and Aaron Mark Drucker, MD.

CMS Open Payments shows 33 general payments to Dr. Dobrowolski from 5 drug and device companies from 2023 to 2025. Consulting fees make up the largest share, 64% of the total. Novartis Pharmaceuticals Corporation paid the most, $8,367.

Dr. Dobrowolski graduated from Dalhousie University, Faculty of Medicine in 2015.